Product Information
Registration Status: ActiveSIN15088P
LATUDA TABLET 40MG is approved to be sold in Singapore with effective from 2016-09-14. It is marketed by DKSH SINGAPORE PTE LTD, with the registration number of SIN15088P.
This product contains Lurasidone 40mg in the form of ORAL TABLET, FILM-COATED. It is approved for ORAL use.
This product is manufactured by Bushu Pharmaceuticals Ltd (Kawagoe Factory) in JAPAN, andOLIC (Thailand) Ltd (Primary and Secondary Packager) in THAILAND.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. (Wikipedia)
Indication
Treatment of schizophrenia.
Mechanism of Action
Lurasidone is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and dopamine activity) to improve cognition. It is thought that antagonism of serotonin receptors can improve negative symptoms of psychoses and reduce the extrapyramidal side effects that are often associated with typical antipsychotics.
Pharmacokinetics
- Absorption
- Lurasidone is readily absorbed and quickly reaches maximal concentrations (Cmax) within 1-4 hours. When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours. This occurs regardless of fat or caloric content. Bioavailability = 9-19%.
- Distribution
- 6173 L
- Metabolism
- Lurasidone is metabolized by CYP3A4 in which its major active metabolite is referred to as ID-14283 (25% of parent exposure). Its two minor metabolites are referred to as ID14326 and ID11614 which make up 3% and 1% of parent exposure respectively. Its two non-active metabolites are referred to as ID-20219 and ID-20220.
- Elimination
Clearance
3902 mL/min
Active Ingredient/Synonyms
Lurasidona | Lurasidonum | Lurasidone |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.